Practical application of fully automated measurement of CSF biomarkers

Hisashi Nojima¹⁾, Akira Kushida²⁾

¹⁾FUJIREBIO INC., R&D Division, Product Development Department, Product Designing 1st section
²⁾FUJIREBIO INC., Product Planning Division, Product Planning Department 1, Product Planning Section 1

Alzheimer’s disease （AD） is the most common cause of dementia in elderly people, and cerebral amyloid β （Aβ） plaques and neurofibrillary tangles arising in the brain are the hallmarks of AD.　Since disease-modifying therapies for AD is expected to be approved in Japan in due course, preparing a fully automated measurement of CSF biomarkers to diagnose AD accurately is essential.　AD biomarkers, especially cerebrospinal fluid （CSF） biomarkers, are well-established in the research setting, but the use of CSF biomarkers in routine clinical practice still has limited.　Here we review the existing CSF biomarkers for AD and discuss practical application of fully automated measurement of CSF biomarkers.

Address correspondence to Dr. Hisashi Nojima, FUJIREBIO INC., R&D Division, Product Development Department, Product Designing 1st section （Komiya 51, Hachioji, Tokyo 192-0031）